ESTRO 2022 - Abstract Book

S1058

Abstract book

ESTRO 2022

and overall survival (OS) were retrospectively evaluated using Kaplan-Meier method. A Multivariate analysis of variance was performed to assess possible prognostic factors, such as dose, primary tumor, disease-free interval, SUVmax post-treatment PET/CT evaluation.

Fig 1. Patient with colorectal cancer with 3 lung nodules treated with SABR.

Results A total of 110 nodules of 80 patients were irradiated. Median follow-up was 42 months. Median age was 75 years (range 24- 94). Median tumor size was 1.5 cm (range 0.5-4.5 cm). 74.5% were peripherals and 25.5% were central nodules. Pathologically confirmed metastases were 16. A total of 79 tumors were oligometastases, 10 oligopersistence, and 21 oligoprogressive. According to primary tumor: Lung cancer 30 patients (37%), Colorectal cancer 29 patients (36.25%), Soft tissue tumors 7 patients (8.7%), Head & neck cancer 6 patients (7%) and other histologies 8 patients (8.75%). Median total dose was 53.9 Gy. At 3 years follow-up: in lung cancer LC was 94.4%, OS 69.4% and CSS 77.7%. in colorectal cancer: LC 63.6%, OS 72%, CSS 75%, soft tissue tumors LC of 90%, OS and CSS 72% and in Head & neck cancer LC was100% and CSS 81% (see table 1). There was no significant difference in prognostic factors in multivariate analysis.

Table 1. Survival data at 1, 2 and 3 years

Conclusion Our study showed an excellent LC, CSS and OS for all primary tumors. Comparatively, LC remains lower in colorectal cancer and the lowest OS at 3 year was observed in lung cancer. Further studies need to be performed to specify the possible prognostic factors.

PO-1254 SBRT vs 3D-CRT FOR OLIGOMETASTATIC BONE NSCLC

G. Marvaso 1 , E. Milovanova 2 , R. Santamaria 1 , S. Volpe 1 , G. Corrao 1 , M. Zaffaroni 3 , M. Pepa 3 , M.G. Vincini 3 , O. D'Ecclesiis 4 , S. Gandini 4 , G. Piperno 3 , A. Ferrari 3 , R. Orecchia 5 , B.A. Jereczek-Fossa 1 1 IEO, European Institute of Oncology IRCCS; University of Milan, Division of Radiation Oncology; Department of Oncology and Hematoncology, Milan, Italy; 2 University of Milan, Department of Oncology and Hematoncology, Milan, Italy; 3 IEO, European Institute of Oncology IRCCS, Division of Radiation Oncology, Milan, Italy; 4 IEO, European Institute of Oncology IRCCS, Department of Experimental Oncology, Milan, Italy; 5 IEO, European Institute of Oncology IRCCS, Scientific Directorate, Milan, Italy